|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 5/02/23 Nymox Pharmaceutical Corp. 20-F 12/31/22 105:5.5M Pubco Reporting … Inc/FA |
Document/Exhibit Description Pages Size
1: 20-F Annual or Annual-Transition Report by a Foreign HTML 1.46M
Non-Canadian Issuer
4: EX-13.A Annual or Quarterly Report to Security Holders HTML 24K
5: EX-13.B Annual or Quarterly Report to Security Holders HTML 24K
2: EX-12.A Statement re: the Computation of Ratios HTML 28K
3: EX-12.B Statement re: the Computation of Ratios HTML 28K
11: R1 Cover HTML 96K
12: R2 Consolidated Statements of Comprehensive Loss HTML 70K
13: R3 Consolidated Statements of Financial Position HTML 73K
14: R4 Consolidated Statements of Financial Position HTML 26K
(Parenthetical)
15: R5 Consolidated Statements of Cash Flow HTML 79K
16: R6 Consolidated Statements of Changes in Deficit HTML 49K
17: R7 Business Activities and Basis of Presentation HTML 31K
18: R8 Going Concern Considerations HTML 29K
19: R9 Significant Estimates HTML 26K
20: R10 Significant Accounting Policies HTML 62K
21: R11 New Accounting Standards and Interpretations HTML 31K
22: R12 Property and Equipment HTML 79K
23: R13 Intangible Assets HTML 26K
24: R14 Accounts Payable and Accrued Liabilities HTML 37K
25: R15 Operating Leases and Commitments HTML 56K
26: R16 Share Capital HTML 37K
27: R17 Stock Options HTML 58K
28: R18 Share Based Compensation HTML 34K
29: R19 Warrants HTML 53K
30: R20 Income Taxes HTML 46K
31: R21 Earnings Per Share HTML 33K
32: R22 Financial Instruments Fair Value Disclosures HTML 26K
33: R23 Finance Income and Finance Costs HTML 39K
34: R24 Segment Disclosures HTML 39K
35: R25 Concentrations HTML 32K
36: R26 Related Party Transactions HTML 37K
37: R27 Research and Development Expenses HTML 37K
38: R28 Personnel Expenses HTML 35K
39: R29 Capital Disclosures and Financial Risk HTML 26K
40: R30 Foreign Exchange Risk HTML 27K
41: R31 Credit Risk HTML 28K
42: R32 Interest Rate Risk HTML 26K
43: R33 Liquidity Risk HTML 33K
44: R34 Commitments and Contingencies HTML 27K
45: R35 Subsequent Events HTML 27K
46: R36 Significant Accounting Policies (Policies) HTML 85K
47: R37 Significant Accounting Policies (Tables) HTML 28K
48: R38 New Accounting Standards and Interpretations HTML 30K
(Tables)
49: R39 Property and Equipment (Tables) HTML 78K
50: R40 Accounts Payable and Accrued Liabilities (Tables) HTML 36K
51: R41 Operating Leases and Commitments (Tables) HTML 55K
52: R42 Share Capital (Tables) HTML 35K
53: R43 Stock Options (Tables) HTML 56K
54: R44 Share Based Compensation (Tables) HTML 32K
55: R45 Warrants (Tables) HTML 51K
56: R46 Income Taxes (Tables) HTML 46K
57: R47 Earnings Per Share (Tables) HTML 32K
58: R48 Finance Income and Finance Costs (Tables) HTML 38K
59: R49 Segment Disclosures (Tables) HTML 38K
60: R50 Concentrations (Tables) HTML 31K
61: R51 Related Party Transactions (Tables) HTML 33K
62: R52 Research and Development Expenses (Tables) HTML 37K
63: R53 Personnel Expenses (Tables) HTML 34K
64: R54 Liquidity Risk (Tables) HTML 31K
65: R55 Significant Accounting Policies (Details) HTML 31K
66: R56 Significant Accounting Policies (Details HTML 27K
Narrative)
67: R57 Property and Equipment (Details) HTML 51K
68: R58 Property and Equipment (Details Narrative) HTML 27K
69: R59 Intangible Assets (Details Narrative) HTML 31K
70: R60 Accounts Payable and Accrued Liabilities (Details) HTML 34K
71: R61 Operating Leases and Commitment (Details) HTML 29K
72: R62 Operating Leases and Commitment (Details 1) HTML 33K
73: R63 Operating Leases and Commitment (Details HTML 34K
Narrative)
74: R64 Share Capital (Details) HTML 28K
75: R65 Share Capital (Details Narrative) HTML 35K
76: R66 Stock Options (Details) HTML 52K
77: R67 Stock Options (Details 1) HTML 40K
78: R68 Stock Options (Details Narrative) HTML 29K
79: R69 Share Based Compensation (Details) HTML 32K
80: R70 Share Based Compensation (Details Narrative) HTML 38K
81: R71 Warrants (Details) HTML 36K
82: R72 Warrants (Details Narrative) HTML 34K
83: R73 Income Taxes (Details) HTML 37K
84: R74 Income Taxes (Details 1) HTML 29K
85: R75 Income Taxes (Details Narrative) HTML 29K
86: R76 Earnings Per Share (Details) HTML 30K
87: R77 Finance Income and Finance Costs (Details) HTML 40K
88: R78 Segment Disclosures (Details) HTML 39K
89: R79 Concentrations (Details) HTML 32K
90: R80 Related Party Transactions (Details) HTML 34K
91: R81 Related Party Transactions (Details Narrative) HTML 44K
92: R82 Research and Development Expenses (Details) HTML 38K
93: R83 Personnel Expenses (Details) HTML 33K
94: R84 Personnel Expenses (Details Narrative) HTML 30K
95: R85 Capital Disclosures and Financial Risk (Details HTML 26K
Narrative)
96: R86 Foreign Exchange Risk (Details Narrative) HTML 26K
97: R87 Credit Risk (Details Narrative) HTML 26K
98: R88 Interest Rate Risk (Details Narrative) HTML 26K
99: R89 Liquidity Risk (Details) HTML 33K
100: R90 Subsequent Events (Details Narrative) HTML 27K
103: XML IDEA XML File -- Filing Summary XML 194K
101: XML XBRL Instance -- nymox_20f_htm XML 1.34M
102: EXCEL IDEA Workbook of Financial Reports XLSX 149K
8: EX-101.CAL XBRL Calculations -- nymox-20221231_cal XML 150K
10: EX-101.DEF XBRL Definitions -- nymox-20221231_def XML 362K
7: EX-101.LAB XBRL Labels -- nymox-20221231_lab XML 749K
9: EX-101.PRE XBRL Presentations -- nymox-20221231_pre XML 635K
6: EX-101.SCH XBRL Schema -- nymox-20221231 XSD 268K
104: JSON XBRL Instance as JSON Data -- MetaLinks 264± 345K
105: ZIP XBRL Zipped Folder -- 0001640334-23-000736-xbrl Zip 259K
EXHIBIT 13 (a)
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
I, Paul Averback, President and CEO of Nymox Pharmaceutical Corporation, do hereby certify that, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the information contained in the Annual Report for the period ended December 31, 2022 of Nymox Pharmaceutical Corporation and filed with the Securities and Exchange Commission, fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 and the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Nymox Pharmaceutical Corporation
| Date: May 1, 2023 | ||
|
| ||
| By: | ||
| President and Chief Executive Officer |
||
| Nymox Pharmaceutical Corporation | ||
| This ‘20-F’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 5/2/23 | |||
| 5/1/23 | ||||
| For Period end: | 12/31/22 | NT 20-F | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/03/11 Nymox Pharmaceutical Corp. 20-F/A 12/31/10 7:474K e3 Fil… Computershare/FA 6/30/04 Nymox Pharmaceutical Corp. 20-F 12/31/03 7:1.1M Foley & Lardner/FA 6/27/02 Nymox Pharmaceutical Corp. 20-F 12/31/01 2:246K Foley & Lardner/FA |